scholarly journals A novel orally active gonadotropin‐releasing hormone antagonist, relugolix, is a potential substitute for injectable GnRH antagonists in controlled ovarian stimulation in assisted reproductive technology

2021 ◽  
Author(s):  
Michiko Hamada ◽  
Michiharu Horikawa ◽  
Chie Ensaka ◽  
Megumi Enomoto ◽  
Rena Ishii ◽  
...  
Keyword(s):  
Assisted Reproductive Technology ◽  
Ovarian Stimulation ◽  
Reproductive Technology ◽  
Gonadotropin Releasing Hormone ◽  
Controlled Ovarian Stimulation ◽  
Gnrh Antagonists ◽  
Releasing Hormone ◽  
Orally Active

scholarly journals Analysis of the clinical efficiency of human menopausal gonadotropins in the assisted reproductive technology program

2021 ◽  
pp. 34-41
Author(s):  
Yu. A. Drapkina ◽  
N. P. Makarova ◽  
V. Yu. Smolnikova
Keyword(s):  
Assisted Reproductive Technology ◽  
Ovarian Stimulation ◽  
Ovarian Function ◽  
Laboratory Data ◽  
Reproductive Technology ◽  
Gonadotropin Releasing Hormone ◽  
Human Menopausal Gonadotropin ◽  
Technology Program ◽  
Releasing Hormone ◽  
Technology Programs

Introduction. Comparative analysis of urinary and recombinant gonadotropins is ongoing to improve the efficiency of assisted reproductive technology programs. Particular interest focused on the identification of individual groups of patients with maximal efficacy of using certain ovarian stimulation drugs in an assisted reproductive technology program.Objective. To review the application of Menopur Multidose 1200 IU for ovarian stimulation in assisted reproductive technology protocols with gonadotropin-releasing hormone agonists (GnRH) or gonadotropin-releasing hormone antagonists (GnRH antagonists) in the current clinical practice.Materials and methods. The study retrospectively enrolled 4,080 women aged 20-43 years. Ovarian stimulation in the Assisted Reproductive Technology program was performed using the GnRH antagonist protocol in 65.8% of patients and the GnRH agonist protocol with Menopur Multidose 1200 IU with or without the additional Menopur 75 IU in 34.2% of women.Results. Clinical and laboratory data of the patients, stimulated cycle parameters, characteristics of the embryological stage, and results of the assisted reproductive technology program were analyzed. The frequency of obtaining degenerated oocytes did not exceed 5%. The relative number of blastocysts of good quality was 59.9%, while for patients in the older age group, the figure was 54.6. The average pregnancy rate in patients in the “Menopur Multidose 1200 IU p/k” group was 39.3%, which corresponds to high-performance indicators of the assisted reproductive technology program.Conclusions. Administration of highly purified human menopausal gonadotropin (hMG) (Menopur Multidose 1200 IU) to stimulate ovarian function in patients of different ages is accompanied by an adequate number of mature oocytes, good quality blastocysts, and satisfactory clinical pregnancy rates. Thus, highly purified human menopausal gonadotropin is not inferior to recombinant follicle-stimulating hormone(r-FSH) concerning the efficacy of assisted reproductive technology programs.

Potential implications of gonadotropin-releasing hormone analogues in assisted reproductive technology

2022 ◽  
pp. 209-224
Author(s):  
Joseph R.D. Fernandes ◽  
Moitreyi Das ◽  
Kavya Chandra ◽  
Indrashis Bhattacharya ◽  
Arnab Banerjee
Keyword(s):  
Assisted Reproductive Technology ◽  
Reproductive Technology ◽  
Gonadotropin Releasing Hormone ◽  
Releasing Hormone
Sign in / Sign up

Export Citation Format

Share Document